Biogen Inc. (NASDAQ:BIIB) – Investment analysts at Piper Sandler lowered their Q4 2022 earnings per share (EPS) estimates for Biogen in a research report issued to clients and investors on Monday, December 20th. Piper Sandler analyst C. Raymond now anticipates that the biotechnology company will earn $4.69 per share for the quarter, down from their prior estimate of $4.82. Piper Sandler has a “Overweight” rating and a $390.00 price objective on the stock.